Miguel Arcinas, MBA

Venture Partner

Miguel Arcinas is a Venture Partner at Raven. Miguel’s primary responsibility is to lead the corporate development function for various portfolio companies. Prior to Raven, Miguel most recently served as Chief Business Officer of Capstan Therapeutics, which was acquired by AbbVie in 2025. Prior to Capstan, Miguel was Vice President of Corporate Development and Investor Relations at Silverback Therapeutics, where he played a key role in the company’s Series C financing, IPO, and merger activities. Earlier in his career, Miguel held progressively more senior corporate development and operational roles at multiple biopharmaceutical companies, including Synthorx, where he contributed to the company’s acquisition by Sanofi, as well as Acadia Pharmaceuticals and Ignyta. Miguel brings more than 15 years of cross-functional experience across biotech corporate strategy, business development, investor relations, and clinical operations. Miguel holds a BS from UCLA and a MBA from the University of Chicago Booth School of Business.